|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7800 EUR | -2.01% |
|
-8.67% | -18.75% |
| 02/03 | Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 2-MAR-2026. | CI |
| 25/02 | Adocia SA Announces Board Changes | CI |
Company Valuation: Transgene
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 137.9 | 247.8 | 164.8 | 137.8 | 89.75 | 213.6 | 213.6 | - |
| Change | - | 79.73% | -33.52% | -16.38% | -34.86% | 137.97% | 0% | - |
| Enterprise Value (EV) 1 | 129.9 | 214.9 | 151.4 | 139.4 | 83.48 | 142.7 | 183.2 | 247 |
| Change | - | 65.43% | -29.53% | -7.95% | -40.12% | 70.92% | 28.38% | 34.83% |
| P/E ratio | -7.85x | -12.1x | -5.02x | -6.23x | -2.34x | -7.09x | -5.57x | -3.39x |
| PBR | 2.74x | 3.69x | 4.38x | 8.82x | 5.92x | 7.09x | 2.44x | -15.6x |
| PEG | - | - | -0.1x | 0.2x | -0.1x | 0.1x | -0.2x | -0.1x |
| Capitalization / Revenue | 13.9x | 14.2x | 15.9x | 17.4x | 14.1x | 33.9x | 33.9x | 33.9x |
| EV / Revenue | 13.1x | 12.3x | 14.6x | 17.6x | 13.1x | 22.6x | 29.1x | 39.2x |
| EV / EBITDA | -5.85x | -10.2x | -5.37x | -4.9x | -2.43x | -4.07x | -4.11x | -3.47x |
| EV / EBIT | -5.41x | -9.14x | -5.06x | -4.64x | -2.34x | -4x | -4.05x | -3.44x |
| EV / FCF | -4.39x | -6.59x | -6.94x | -1,408x | -3.12x | -4.4x | -5.65x | -4.44x |
| FCF Yield | -22.8% | -15.2% | -14.4% | -0.07% | -32% | -22.7% | -17.7% | -22.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.21 | -0.21 | -0.33 | -0.22 | -0.29 | -0.11 | -0.14 | -0.23 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 9.915 | 17.41 | 10.34 | 7.9 | 6.353 | 6.3 | 6.3 | 6.3 |
| EBITDA 1 | -22.21 | -21 | -28.22 | -28.48 | -34.38 | -35.1 | -44.6 | -71.1 |
| EBIT 1 | -23.99 | -23.52 | -29.9 | -30.05 | -35.66 | -35.7 | -45.2 | -71.7 |
| Net income 1 | -17.23 | -19.54 | -32.8 | -22.33 | -33.97 | -31.2 | -39.6 | -62.9 |
| Net Debt 1 | -7.99 | -32.93 | -13.31 | 1.629 | -6.274 | -70.9 | -30.4 | 33.4 |
| Reference price 2 | 1.6480 | 2.5400 | 1.6580 | 1.3700 | 0.6800 | 0.7800 | 0.7800 | 0.7800 |
| Nbr of stocks (in thousands) | 83,677 | 97,576 | 99,370 | 1,00,566 | 1,31,990 | 2,73,827 | 2,73,827 | - |
| Announcement Date | 10/03/21 | 16/03/22 | 16/03/23 | 27/03/24 | 27/03/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.24x | 23.34x | -4.19x | - | 25Cr | |
| 42.74x | 10x | 36.07x | 0.03% | 4.48TCr | |
| 15.94x | 5.69x | 12.52x | 1.88% | 4.03TCr | |
| -51.84x | 17.45x | -57.65x | -.--% | 3TCr | |
| -17.5x | 4.48x | -8.41x | -.--% | 2.18TCr | |
| 27.64x | 5.7x | 15.82x | -.--% | 1.91TCr | |
| 22.04x | 4.19x | 13.68x | -.--% | 1.67TCr | |
| -329.09x | 27.33x | 1504.74x | -.--% | 1.35TCr | |
| -14.2x | 6349.59x | -18.15x | -.--% | 1.25TCr | |
| -169.65x | 41.3x | -164.02x | -.--% | 1.21TCr | |
| Average | -48.12x | 648.91x | 133.04x | 0.21% | 2.11TCr | |
| Weighted average by Cap. | -24.48x | 386.06x | 89.39x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- TNG Stock
- Valuation Transgene
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition